Home › Peripheral Arterial Disease › South Carolina › Greenville
Peripheral Arterial Disease clinical trials in Greenville, SC
5 studies for Peripheral Arterial Disease are looking for participants at sites in and around Greenville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
EVERO Drug-coated Balloon (DCB) Randomized Trial
Recruiting
- Prisma Health Memorial, Greenville
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
RecruitingPhase 2/3
- CN Clinical Research LLC, Greenville
Serranator POINT FORCE Registry
RecruitingObservational study
- Prisma Health, Greenville
Auryon Atherectomy System With Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone
RecruitingPhase 4
- Prisma Heath-University Medical Group, Greenville
Pounce™ Thrombectomy System Retrospective Registry
RecruitingObservational study
- Prisma Health Upstate, Greenville
About Peripheral Arterial Disease
Peripheral arterial disease (PAD) happens when there is a narrowing of the blood vessels outside of your heart. Learn about symptoms and treatment.
More about Peripheral Arterial Disease on MedlinePlus
Peripheral Arterial Disease trials in other cities
- Boston, MA10 studies
- Dallas, TX9 studies
- Cleveland, OH9 studies
- Chicago, IL9 studies
- Houston, TX8 studies
- Omaha, NE7 studies
- Gainesville, FL7 studies
- Nashville, TN6 studies
- Miami, FL6 studies
- Minneapolis, MN6 studies
- Detroit, MI6 studies
- Aurora, CO6 studies
Other studies in Greenville
- Non-Small Cell Lung Cancer15 studies
- Breast Cancer12 studies
- Acute Myeloid Leukemia10 studies
- Cancer (all types)9 studies
- Obesity9 studies
- Lung Cancer9 studies
- Overweight8 studies
- Prostate Cancer7 studies
- Colorectal Cancer7 studies
- Stomach Cancer6 studies
- Burkitt Lymphoma5 studies
- Melanoma5 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.